A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis

ConclusionsSurvival for patients with systemic AL amyloidosis has improved for patients at all stages of disease in the present era of rapid advancements in light chain-reducing therapies. Cardiac biomarkers at diagnosis, but not baseline dFLC ≥18 mg/dl, continue to provide important prognostic information.Central Illustration
Source: JACC: Heart Failure - Category: Cardiology Source Type: research